337 episodes

Welcome to the Ophthalmology Innovation Podcast Where you get Candid Conversations with the Leaders and Drivers of Ophthalmic Innovation. OIS is the Largest and Original Producer of World-Class Ophthalmology Innovation Conferences and Content Since 2009.

OIS Podcast OIS Podcast

    • Business
    • 4.6 • 29 Ratings

Welcome to the Ophthalmology Innovation Podcast Where you get Candid Conversations with the Leaders and Drivers of Ophthalmic Innovation. OIS is the Largest and Original Producer of World-Class Ophthalmology Innovation Conferences and Content Since 2009.

    Flying Eye Hospitals and Machine Mentoring, with Orbis International

    Flying Eye Hospitals and Machine Mentoring, with Orbis International

    Orbis International has been a pioneer in preventing and treating avoidable blindness for forty years. While much of that work takes plane on its Flying Eye Hospital, the organization also uses advanced technology to bring quality care to individuals worldwide.
    Cybersight is the global nonprofit’s telemedicine platform. Through it, the organization offers 24/7 live peer-to-peer consults for specialists worldwide. Over 24,000 eye care practitioners have sought expert opinions through the platform, gaining access to mentorship and advice they wouldn’t have otherwise. Users can also access live surgical demonstrations, courses, and other training: its library is free for all professionals.
    Orbis also leverages artificial intelligence to help improve access to eye care. Cybersight consult supports AI-grading of color fundus images attached to consult cases. In seconds, a doctor in a remote region can get an interpretation of an image to aid in diagnosis of diabetic retinopathy, hemorrhages, glaucoma, and other conditions.
    These are just two of the many ways Orbis International continues its fight against avoidable blindness. As Hunter Cherwek, MD, vice president of clinical services for Orbis, makes clear: 75% of visual impairment is preventable and 90% of those preventable conditions occur in low- and middle-income countries.


    Hosted by Rob Rothman, MD, this episode covers these and other topics:


    How Cybersight democratizes technology-driven eye care.Cybersight in practice. Full-stack machine learning engineer Gabriella Lanouette describes how it’s used in the real world and how it lessens the burden for clinicians.How Orbis International is developing more globally representative datasets to eliminate geographical and other biases in research.Managing a non-governmental organization. Venture partner, consultant, and Orbis UK board of trustees member Sophia Pathai, MD, Ph.D., MPH, discusses how the board balances fiscal and fiduciary responsibilities with the organization’s mission.How Orbis fundraises at the corporate level, worldwide.How you can get involved. Hint: You don’t have to sit on a plane…[Listen to the Podcast]

    • 39 min
    Early-Stage Retina Drug Development Financing

    Early-Stage Retina Drug Development Financing

    • 27 min
    OIS Retina 2022: How to Execute New Treatments for Dry AMD and GA

    OIS Retina 2022: How to Execute New Treatments for Dry AMD and GA

    A group of experts in AMD and geographic atrophy discussed two GA treatments in Phase III studies: Apellis’s pegcetacoplan and Iveric Bio’s Zimura.
    If approved, these therapies will potentially slow lesion growth and preserve vision in patients with GA. Because they require monthly or bimonthly injections, they may also dramatically increase workloads for already overtaxed retina specialists.
    David Boyer, MD, of Retina Vitreous Associates Medical Group, said they’ll adapt. Somehow. Tarek Hassan, MD, partner and director of vitreoretinal training at Associated Retinal Consultants, agreed, noting the current working model will have to change. Somehow. “If we think we’re helping our patients we’ll figure it out,” he said.
    For better or worse, the rollout could be a gradual one. New-onset exudation has been observed in both pegcetacoplan and Zimura. This may spook some physicians, the panel noted, and they’ll take a watch-and-wait approach. Even so, it’s an exciting development for a challenging condition.
    Listen to the podcast today to hear our panel of retina experts discuss these and other questions related to dry AMD and GA treatment:
    Who are the ideal candidates for the forthcoming therapies from Iveric Bio and Apellis?How do you convince asymptomatic GA patients to initiate and continue treatment?How will artificial intelligence play a role in building a case for these therapies?Why do some patients with GA experience exudation?How do researchers determine clinical endpoints for GA? How does foveal center point involvement play a role?How do you decide on a proper treatment path?What therapies, drug delivery platforms, and/or technologies on the horizon are you excited about?[Listen to the Podcast]


    Speakers:
    David Boyer, MD - Retina Vitreous Associates Medical Group
    Tarek S. Hassan, MD, Professor of Ophthalmology - Oakland University William Beaumont School of Medicine / Partner and Director of Vitreoretinal Training - Associated Retinal Consultants
    Erin Henry, PhD, Executive Director, Head of Ophthalmology - NGM Biopharmaceuticals
    J. Jill Hopkins, MD, SVP & Global Head, Ophthalmology Development Unit - Novartis
    Caroline R. Baumal, MD, Professor of Ophthalmology, Co-director of Retina Service - New England Eye Center, Tufts Medical Center

    • 22 min
    Spotlight On Gene & Cell Therapy

    Spotlight On Gene & Cell Therapy

    • 23 min
    Early-Stage Retina Drug Development Financing

    Early-Stage Retina Drug Development Financing

    • 38 min
    Ashley Brissette, MD: Academic and Eye-Focused Skincare Entrepreneur

    Ashley Brissette, MD: Academic and Eye-Focused Skincare Entrepreneur

    OIS Podcast host Paul Karpecki, OD, sits down with Ashley Brissette, MD, who just launched an eye-focused cosmetic skincare line called Eye Revive by Daily Practice. 
    Now assistant professor of ophthalmology at  Weill Cornell Medicine, New York Presbyterian Hospital, Dr. Brissette talks about her journey to physician and entrepreneur.
    We get to hear how the Canadian-born, one-time performing-arts student transitioned into medicine and made her way to New York City, where her roster of patients includes the New York Rangers and Savannah Guthrie of NBC News and “The Today Show.”
    After consistently being asked by female patients which consumer products were best for the skin around the eyes, Dr. Brissette decided to formulate the first and only 3-in-1 product to cleanse, hydrate, and remove makeup.
    This didn’t come without its share of challenges and lessons. Listen in to learn more about this impressive young ophthalmologist and new business founder.  
    Click “play” to listen.

    • 24 min

Customer Reviews

4.6 out of 5
29 Ratings

29 Ratings

You Might Also Like

Eyetube
NPR
Retina Synthesis
NPR
Guy Raz | Wondery
Jason Calacanis